Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536

Expert Opin Ther Pat. 2020 Feb;30(2):83-86. doi: 10.1080/13543776.2020.1709445. Epub 2020 Jan 3.


Introduction: TIGIT is an inhibitory receptor expressed by lymphocytes that suppresses the immune response against tumor cells. There is a great need to discover and develop new therapies focused on inhibiting the action of TIGIT and consequently improving the immune response in the various types of cancer. Authors of WO2018102536 patent propose a method to eradicate cancer utilizes anti-TIGIT antibody, etigilimab, in combination with anti-PD-1/PD-L1 antibody, nivolumab.Areas covered: WO2018102536 patent describes a method of cancer combinatorial treatment consisting of the utilization of either a pharmaceutical cocktail containing anti-TIGIT and an anti-PD-L1 antibody.Expert opinion: The results of the clinical trials only support trials regarding the tolerability of therapy with etigilimab, but does not show data related to the combined use of etigilimab and nivolumab.

Keywords: PD-1; TIGIT; cancer; combination therapy; immunotherapy; patent.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • B7-H1 Antigen / antagonists & inhibitors
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Nivolumab / administration & dosage*
  • Patents as Topic
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Receptors, Immunologic / antagonists & inhibitors


  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, Immunologic
  • TIGIT protein, human
  • Nivolumab